ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.
Advertisements

VALENCE SOF + RBV Not randomised Open label* ≥ 18 years Chronic HCV infection Genotype 2 or 3 HCV RNA ≥ 10,000 IU/ml Treatment naïve or prior IFN-based.
Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.
ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,
Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.
ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.
CURRY  Design Open-label CURRY Study: SOF + RBV for HCV with liver cancer before transplantation ≥ 18 years Chronic HCV infection Any genotype HCV RNA.
Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:
OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.
FUSION  Design  Objectives –SVR ≥ 20% compared with historical control of 25%, 97% power –Difference of SVR > 20% between the 2 groups, 82% power SOF.
ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.
FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =
AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.
SOF + PEG-IFN  -2a + RBV Open-label Single arm ≥ 18 years Chronic HCV infection Genotype 1, 4, 5 or 6 Treatment-naïve HCV RNA ≥ 10,000 IU/ml Compensated.
SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.
Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.
ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.
ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.
W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.
OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.
SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.
SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.
SOF/VEL 400/100 mg qd N = 75 W24 SOF/VEL > 18 years Chronic HCV infection Genotype 1 to 6 Naïve or treatment-experienced No prior treatment with NS5A or.
 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg BID –RBV.
SMV + DCV + SOF Open label Chronic HCV infection Genotype 1 or 4 Treatment-naïve or pre-treated with PEG-IFN ± RBV Portal hypertension or liver decompensation.
ALLY-3  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI DCV 60 mg qd + SOF 400 mg qd Not randomised Open-label ALLY-3 Study: DCV + SOF for.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.
Forns X. J Hepatology 2015; 63: C-SALVAGE Study: grazoprevir + elbasvir + RBV in genotype 1 with failure to PI-based regimen –NS3 and NS5A RAVs.
SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir.
Asselah T. AASLD 2015, Abs. 714 Randomisation 1:1 Open-label years HCV genotype 4 HCV RNA ≥ 1,000 IU/ml Naïve or pre-treated with PEG-IFN + RBV (Part.
OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.
No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
SOF + RBV Randomisation* 1 : 1 : 1 Open-label BOSON Study: SOF + RBV + PEG-IFN for genotypes 2 and 3 ≥ 18 years Chronic HCV infection Genotype 2, treatment-
 Design  Objective –Difference in SVR ≥ 40% between the 2 groups, 99% power SOF + RBV Placebo Randomisation 3 : 1* Double blind HCV infection Genotype.
Open-label W24 ≥ 18 years Chronic HCV infection All genotypes HCV RNA ≥ 10,000 IU/ml Liver transplantation months earlier Child Pugh ≤ 7 and MELD.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, by ITT, descriptive analysis OBV/PTV/r + DSV + RBV No randomisation Open-label CORAL-I Study cohort.
LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.
SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + DSV + SOF +RBV Open-label W24 ≥ 18 years Chronic HCV Genotype 1 Prior failure on DAA-regimen.
LDV/SOF Open-label Chronic HCV infection Genotype 1 Failure to achieve SVR 12 on a short-course of 1 st line LDV/SOF-containing regimen No cirrhosis N.
PHOTON-1  Design  Objective –SVR 12 with 2-sided 95% CI, descriptive analysis –Multivariate analyses of predictors of SVR 12 SOF + RBV, N= 114 SOF +
SOF/VEL 400/100 mg qd N = 106 W12 > 18 years Chronic HCV infection Genotype 1-6 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis allowed*
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.
No HBV or HIV co-infection
SOF + RBV GT2 Japanese SOF + RBV Open-label Japanese SOF + RBV Study: SOF + RBV in genotype 2  Design W12 Japanese patients ≥ 20 years Chronic HCV infection.
No cirrhosis or compensated cirrhosis * No HBV or HIV coinfection
Genotype 1 HCV infection Stable immunosuppressive therapy
No HBV or HIV co-infection
C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis
Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study
Design No randomisation Open-label W12 W years HCV genotype 1
PHOTON-2 Study: SOF + RBV in HCV-HIV co-infection
ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.
GEODE-II Study: OBV/PTV/r + DSV + low dose RBV in genotype 1a
No cirrhosis or compensated cirrhosis** No HBV or HIV co-infection
QUARTZ II-III : OBV/PTV/r + SOF RBV in genotype 2 or 3
SOF/VEL + GS-9857 in genotypes 1-6 Phase II
LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1
ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.
ION-3 Study: LDV/SOF + RBV for naïve genotype 1
LDV/SOF ± RBV in genotype 3 or 6 – Phase 2
ARV-trial.com C-CREST study, Part B: uprifosbuvir (MK-3682)/GZR/ruzasvir (MK-8408) fixed-dose combination + RBV for genotypes 1, 2 and 3 - Phase II Randomisation.
No HBV or HIV co-infection
Presentation transcript:

ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised Open-label ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence W12 N = 53 ≥ 18 years Chronic HCV infection All genotypes Treatment-naïve or experienced NS5A inhibitor-naïve Advanced cirrhosis* or post- liver transplant recurrence** Poordad F. EASL 2015, Abs. L08 Post-transplant recurrence SVR 12 N = 60 Advanced cirrhosis * Child-Pugh A, B or C, MELD score 8-40, hepatocarcinoma allowed ** ≥ 3 months post-transplant, no rejection, any immunosuppressive regimen RBV : 600 mg/day (bid dosing), adjusted to 1000 mg/day, based on hemoglobin and creatinine clearance

Advanced cirrhosis N = 60 Post-transplant N = 53 Median age, years5859 Female37%28% HCV RNA log 10 IU/ml, mean IL28B CC genotype22%25% Genotype 1a 1b % 18% 8% 10% 7% 0 58% 19% 0 21% 0 2% Fibrosis stage by Fibrotest : F0-F2 / F3 / F4-43% / 35% / 30% Baseline characteristics  Advanced cirrhosis cohort –Child Pugh A = 12 (MELD score : 5/12) –B = 32 (2/3 with ascites and/or encephalopathy, MELD score : 25/32) –C = 16 (all with ascites and encephalopathy ; MELD score ≥ 16 : 13/16) ALLY-1 ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence Poordad F. EASL 2015, Abs. L08

SVR 12 (HCV RNA < 25 IU/ml) Advanced fibrosis Post-transplant % N Hepatic encephalopathy ABYesCNo Albumin g/dl Yes≥ 2.8 Genotype 1 AllNo Child-PughAscites < 2.8 GT 1aOther genotypes ALLY-1 ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence Poordad F. EASL 2015, Abs. L08

 NS5A variants (-28, -30, -31, or -93 polymorphisms) detected in 22 of 112 patients –82% (18/22) achieved SVR 12 10/14 in cirrhosis cohort ; 8/8 in post-transplant cohort –90% (81/90) without NS5A polymorphisms achieved SVR 12 39/45 in cirrhosis cohort ; 42/45 in post-transplant cohort  No NS5B-S282 variants detected at baseline or failure Advanced cirrhosisPost-transplant Virologic failures, N10 (9 relapses)3 (all relapses) NS5A RAVs at baseline, n/N * 4/100/3 NS5A RAVs at failure, n/N * 10/103/3 * Assessed by population-based sequencing ALLY-1 ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence Poordad F. EASL 2015, Abs. L08 NS5A resistance-associated variants in patients with virologic failure Baseline resistance polymorphisms

Advanced cirrhosis N = 60 Post-transplant N = 53 Death00 Serious adverse event10 (17%), all unrelated5 (9%), all unrelated Grade 3 or 4 adverse event*11 (18%)4 (8%) Discontinuations due to adverse event All study medications1 (2%) RBV only10 (17%)4 (8%) AE (any grade) in ≥ 10% in either cohort Headache9 (15%)19 (36%) Fatigue11 (18%)15 (28%) Anemia12 (20%)10 (19%) Diarrhea5 (8%)10 (19%) Nausea10 (17%)3 (6%) Arthralgia1 (2%)7 (13%) * 4 events (anemia, non-cardiac chest pain, arthralgia, headache) considered related to study medication Adverse events, n (%) ALLY-1 ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence Poordad F. EASL 2015, Abs. L08

 Summary –SVR 12 achieved by 94% of liver transplant recipients with HCV recurrence Favorable drug-drug interaction profile that did not require dose modification of pre-transplant or immunosuppressant medications No events of graft rejection –SVR 12 in 92% of patients with Child-Pugh class A cirrhosis, 94% in class B, 56% in class C –High SVR 12 rates in GT-3 patients: 83% of advanced cirrhosis, 91% of post-transplant –SVR 12 rate of only 76% in genotype 1 advanced cirrhosis ALLY-1 Poordad F. EASL 2015, Abs. L08 ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence